news
Study shows anticoagulation therapy beneficial for COVID-19 patients
Researchers have demonstrated that all regimens of anticoagulants were far superior to no anticoagulants in COVID-19 patients.
List view / Grid view
Apixaban
article
Summarising 2019: a year of firsts for the EMA
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
news
New anti-clotting drugs linked to lower risk of serious bleeding
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
news
Gene therapy medication provides improvements in severe SMA
Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of the spinal muscular atrophy...
news
Anticoagulant drugs appear to reduce the risk of stroke in patients with AF
Blood-thinning drugs not only reduce the risk of stroke in patients with AF but are also associated with a significant reduction in the risk of dementia...
news
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
news
NICE guidance recommends anti-blood clotting drug apixaban
9 June 2015 | By NICE
NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults...
news
FDA accepts Eliquis® (apixaban) sNDA for review for prophylaxis of deep vein thrombosis following hip or knee replacement surgery
11 July 2013 | By Bristol-Myers Squibb Company
FDA accepted for review a sNDA for Eliquis®
news
ELIQUIS® (apixaban) demonstrated superiority in reducing a composite of recurrent venous thromboembolism and all-cause death without increasing the rate of major bleeding versus placebo during one year of extended treatment
8 December 2012 | By Bristol-Myers Squibb Company
Results of the Phase 3 AMPLIFY-EXT trial...
news
ELIQUIS® (apixaban) receives positive opinion from CHMP
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
news
Bristol-Myers Squibb & Pfizer receive response from FDA for ELIQUIS® (apixaban)
26 June 2012 | By Bristol-Myers Squibb Company / Pfizer
Additional information requested from ARISTOTLE trial results...
news
New data presented on Phase 3 trial of ELIQUIS® (apixaban)
13 November 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial...
news
ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
news
ELIQUIS® (apixaban) approved in Europe for preventing venous thromboembolism
20 May 2011 | By Bristol-Myers Squibb Company
The European Commission has approved ELIQUIS® in the 27 countries of the EU...
news
Apixaban statistically superior to aspirin in reducing the composite of stroke or systemic embolism
10 February 2011 | By Pfizer
Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine...
